Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

NCT06022003 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.

NCT NCT06022003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06022003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Lead sponsor
French Innovative Leukemia Organisation
Phase
Phase 2
Overall status
Recruiting
Start date
January 13, 2024
Completion date
October 31, 2027
Enrollment
33 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult, flt3-itd, flt3-tkd mutation, refractory aml, relapsed adult aml